Esperion Therapeutics, Inc.

ESPR

US29664W1053

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 16:00:00 2026-03-06 EST			5-day change	1st Jan Change
2.720 ^USD	-1.81%		-18.81%	-26.49%

03-05	HLS Therapeutics Inc Announces Nilemdo Is Now Available In Canada For The Reduction Of LDL-Cholesterol In Patients At Risk Of Cardiovascular Disease	CI
03-03	Corstasis Therapeutics, Esperion Therapeutics, Inc. - M&A Call

Esperion Therapeutics and Corstasis Therapeutics announce Esperion's definitive agreement to acquire Corstasis, expanding its cardiovascular franchise with Enbumyst™ (bumetanide nasal spray)

Published on 03/03/2026 at 06:40 am EST

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Esperion Therapeutics, Inc.

03-05	HLS Therapeutics Inc Announces Nilemdo Is Now Available In Canada For The Reduction Of LDL-Cholesterol In Patients At Risk Of Cardiovascular Disease	CI
03-03	Corstasis Therapeutics, Esperion Therapeutics, Inc. - M&A Call
03-03	Esperion Therapeutics to Acquire Corstasis for $75 Million in Cash	MT
03-03	Esperion Therapeutics and Corstasis Therapeutics announce Esperion's definitive agreement to acquire Corstasis, expanding its cardiovascular franchise with Enbumyst™ (bumetanide nasal spray)	RE
03-02	Esperion Therapeutics, Inc. entered into an agreement and plan of merger to acquire Corstasis Therapeutics Inc. for approximately $260 million.	CI
01-14	Esperion Therapeutics, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 02:15 PM
01-14	Esperion Seeks Acquisitions	CI
01-11	Esperion reports $156 to $160 million in preliminary full-year 2025 U.S. net product sales	RE
12-09	Esperion announces inducement grants under Nasdaq Listing Rule	RE
11-25	Esperion Therapeutics Shares Rise After Piper Sandler Initiates Coverage	MT
11-25	Piper Sandler Initiates Coverage on Esperion Therapeutics With Overweight Rating	MT
11-21	Esperion Therapeutics Partner Rolls Out Nexletol Tablets in Japan to Treat Hypercholesterolemia	MT
11-21	Esperion partner Otsuka launches Nexletol in Japan	RE
11-21	Esperion Partner Otsuka Launches NEXLETOL in Japan for the Treatment of Hypercholesterolemia	CI
11-20	Esperion Therapeutics, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-18-2025 08:00 AM

Chart Esperion Therapeutics, Inc.

Duration

Period

ESPR: Dynamic Chart

Esperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). The Company's products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company's NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD). Its NEXLETOL is an ATP Citrate Lyase (ACL), inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine. Its Pipeline product include Next Generation ACLYi.

Employees

304

Sector

Pharmaceuticals

Calendar

03-10 - Earnings release - Q4 2025

More about the company